John P. Schmid
John P. Schmid's purchase track record
How the stock did after each of John P. Schmid's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/9/2024 | XERS | $20K | +49.6% | +53.0% | +12.8% |
| 5/10/2024 | XERS | $10K | +31.8% | +97.2% | +14.8% |
| 3/22/2024 | DSGN | $100K | -11.1% | +54.7% | +8.9% |
| 3/14/2024 | XERS | $10K | +4.2% | +34.3% | +8.6% |
| 11/16/2023 | XERS | $10K | +104.5% | +28.7% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AnaptysBio News Mixes Valuation Views With Litigation Risks. Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BBOT reports inducement grants under Nasdaq Rule 5635(c)(4). BridgeBio Oncology Therapeutics announced that it has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The disclosure confirms the company’s compliance with regulatory reporting requirements for incentive arrangements. While the announcement does not provide details on the size of the grants, it highlights ongoing governance practices.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
XERS Amid Biotech Rally on Wednesday. Benzinga reported a rise in several biotech names, including TriSalus Life Sciences, Lakefront Biotherapeutics, and Editas Medicine, on Wednesday. The lift in the sector may lift XERS as well, given its position in the biotech space. XERS trades near the middle of its 52‑week range and sits above its 11‑day support at $6.17. The recent rally could provide a backdrop for further upside.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Design Therapeutics to Present at Cantor Fitzgerald Healthcare Conference. Design Therapeutics will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference. These events give companies a platform to engage with institutional investors and present their programs. The stock has traded within a 52-week range of $5.28 to $17.25, with analysts maintaining an average price target of $21.00.
Transaction History
| TRAX | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2026 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2026 | View on chart |
| ANAB | ▼ Sell | Open Market | 12,596 | $702K | 3/30/2026 | View on chart |
| ANAB | ▼ Sell | Open Market | 7,527 | $427K | 3/30/2026 | View on chart |
| ANAB | ▼ Sell | Open Market | 522 | $30K | 3/30/2026 | View on chart |
| ANAB | ▼ Sell | Other | 11,068 | $564K | 12/23/2025 | View on chart |
| BBOT | ▲ Buy | Option Exercise | 30,000 | — | 8/11/2025 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2025 | View on chart |
| ANAB | ▼ Sell | Other | 11,068 | $201K | 3/25/2025 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 21,692 | $99K | 1/13/2025 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 20,645 | $176K | 1/13/2025 | View on chart |
| XERS | ▲ Buy | Open Market | 4,515 | $10K | 8/12/2024 | View on chart |
| XERS | ▲ Buy | Open Market | 4,285 | $10K | 8/9/2024 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 3,900 | $0 | 6/15/2024 | View on chart |
| XERS | ▲ Buy | Grant | 50,000 | $0 | 6/5/2024 | View on chart |
| XERS | ▲ Buy | Open Market | 5,400 | $10K | 5/10/2024 | View on chart |
| DSGN | ▲ Buy | Open Market | 17,809 | $67K | 3/25/2024 | View on chart |
| DSGN | ▲ Buy | Open Market | 9,156 | $33K | 3/22/2024 | View on chart |
| XERS | ▲ Buy | Open Market | 4,500 | $10K | 3/14/2024 | View on chart |
| XERS | ▲ Buy | Open Market | 6,500 | $10K | 11/16/2023 | View on chart |
| XERS | ▲ Buy | Grant | 42,500 | $0 | 6/7/2023 | View on chart |
| XERS | ▲ Buy | Grant | 15,000 | $0 | 6/8/2022 | View on chart |
| XERS | ▲ Buy | Grant | 5,659 | — | 10/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Evercore initiates coverage on TRAX with Outperform rating
Evercore ISI Group began coverage of First Tracks Biotherapeutics with an Outperform rating and a $65 price target. This adds to a bullish analyst narrative, as the average target from 11 analysts stands at $71.82. The stock is currently trading near its 52-week low, with recent volume spikes indicating heightened market attention.
Evercore initiates coverage on TRAX with Outperform rating. Evercore ISI Group began coverage of First Tracks Biotherapeutics with an Outperform rating and a $65 price target. This adds to a bullish analyst narrative, as the average target from 11 analysts stands at $71.82. The stock is currently trading near its 52-week low, with recent volume spikes indicating heightened market attention.